Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2011
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EA02
|
| gptkbp:brand |
gptkb:Jakafi
gptkb:Jakavi |
| gptkbp:CASNumber |
941678-49-5
|
| gptkbp:chemicalFormula |
C17H18N6
|
| gptkbp:genericName |
gptkb:ruxolitinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Jakafi
|
| gptkbp:indication |
intermediate or high-risk myelofibrosis
polycythemia vera resistant to hydroxyurea steroid-refractory acute graft-versus-host disease |
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:Incyte_Corporation
|
| gptkbp:mechanismOfAction |
JAK1 and JAK2 inhibitor
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
dizziness headache neutropenia thrombocytopenia bruising |
| gptkbp:usedFor |
gptkb:myelofibrosis
gptkb:polycythemia_vera gptkb:graft-versus-host_disease |
| gptkbp:bfsParent |
gptkb:Jakavi
|
| gptkbp:bfsLayer |
5
|